title: [Male osteoporosis: current treatments and future options].
abstract: OBJECTIVE
  To provide indications for currently approved treatments and future options for male osteoporosis, based on the pathogenetic mechanisms of bone loss in the male sex.
  
  
  METHODS
  Review of the most significant data reported in the literature.
  
  
  RESULTS
  Unhealthy lifestyle habits should be modified. Testosterone replacement is indicated only in patients with diagnosis of hypogonadism. Based on the demonstrated pathogenetic role of estrogen lack in bone loss in men, either low doses of this hormone or selective androgen receptor modulators have been proposed for the treatment of male osteoporosis. Bisphosphonates are the only medications approved by Food and Drug Administration for idiopathic and glucocorticoid-induced osteoporosis in men. As far as anabolic treatments are concerned, there is not agreement on clinical utility of sodium fluoride. Short-term treatment with parathyroid hormone (PTH) seems to be safe and effective in patients with idiopathic osteoporosis, due to its anabolic action. Therapeutic use of growth hormone (GH) and insulin-like growth factor type I (IGF-I), both considered as potential anabolic agents, is still limited because of the high incidence of side effects and relatively transient efficacy, particularly of IGF-I.
  
  
  CONCLUSIONS
  Treatments should be selected on the basis of anti-fracture efficacy of various medications, which has been demonstrated so far only for alendronate and risedronate. Although anabolic agents produce noticeable increase of bone mineral density, is still debated if they also reduce fracture incidence in males with osteoporosis.
authors.affiliation: Ospedale San Giovanni Battista, Università La Sapienza, Roma, Italia.
authors.forename: E
authors.initials: E
authors.lastname: Romagnoli
authors.forename: F
authors.initials: F
authors.lastname: Paglia
authors.forename: S
authors.initials: S
authors.lastname: Dionisi
authors.forename: S
authors.initials: S
authors.lastname: De Geronimo
authors.forename: J
authors.initials: J
authors.lastname: Pepe
authors.forename: R
authors.initials: R
authors.lastname: Di Virgilio
authors.forename: S
authors.initials: S
authors.lastname: Minisola
mesh_terms: D000328:Adult; D015519:Bone Density; D004032:Diet; D004164:Diphosphonates / Q000627:therapeutic use; D050723:Fractures, Bone / Q000517:prevention & control*; D005938:Glucocorticoids / Q000009:adverse effects; D013006:Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000627:therapeutic use; D008019:Life Style; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D010281:Parathyroid Hormone / Q000627:therapeutic use; D012737:Sex Factors; D012969:Sodium Fluoride / Q000627:therapeutic use
chemical_list: D004164:Diphosphonates; D005938:Glucocorticoids; D010281:Parathyroid Hormone; D007334:Insulin-Like Growth Factor I; D012969:Sodium Fluoride; D013006:Growth Hormone